Angiogenix


Public lists: Pharma Startups (4732)

Angiogenix, Inc. is an early-stage biotechnology company developing products for peripheral and cardiac ischemia. The Company's ACCLAIM(tm product candidates are proprietary nitrates focused on replacing a significant share of existing generic nitrate products with worldwide sales of about $3 billion. The Company's Vasotrophin(r product candidate is a novel angiogenic growth factor that stimulates both angiogenesis and arteriogenesis to produce robust new blood vessels. Vasotrophin can be inject...Show all

Angiogenix, Inc. is an early-stage biotechnology company developing products for peripheral and cardiac ischemia. The Company's ACCLAIM(tm product candidates are proprietary nitrates focused on replacing a significant share of existing generic nitrat...Show all

Company (Alive / Active)

Phone: 650-579-6685

Fax:

500 Airport Boulevard
Suite 100
Burlingame, 94010
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Angiogenix $17.8M Jul 21, 2003
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Angiogenix Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 10 investors

Board Members

Competitors

Company Status Description Investors

BioMimetic Therapeutics

Franklin, Tennessee, United States
AcquiredBioMimetic Pharmaceuticals (BMTI) is a biopharmaceutical company focused on the development, commercialization and ultimate marketing of protein therapeutics for tissue and organ regeneration. The Company's lead technologies are for the healing and restoration of bone and other tissues. Its lead products are based on recombinant human platelet-derived growth factor BB (rhPDGF-BB). In March 2013, BioMimetic Therapeutics was acquired by Wright Medical Group. The valuation of BioMimetic Therapeuti...Show allLogin to see details

ImaRx Therapeutics

Redmond, Washington, United States
Alive / ActiveWe are a biopharmaceutical company developing and commercializing therapies for vascular disorders. Our research and development efforts are focused on therapies for stroke and other vascular disorders, using our proprietary microbubble technology to treat vascular occlusions, or blood vessel blockages, as well as the resulting ischemia, which is tissue damage caused by a reduced supply of oxygen. In addition to the brain and the lungs, blood clots can block blood flow and cause damage to o...Show allLogin to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)